glucagon has been researched along with efavirenz in 1 studies
| Studies (glucagon) | Trials (glucagon) | Recent Studies (post-2010) (glucagon) | Studies (efavirenz) | Trials (efavirenz) | Recent Studies (post-2010) (efavirenz) |
|---|---|---|---|---|---|
| 26,039 | 1,498 | 3,054 | 3,110 | 631 | 1,611 |
| Protein | Taxonomy | glucagon (IC50) | efavirenz (IC50) |
|---|---|---|---|
| Chain A, POL POLYPROTEIN | Human immunodeficiency virus 1 | 0.2612 | |
| Chain A, POL POLYPROTEIN | Human immunodeficiency virus 1 | 0.2612 | |
| Chain B, POL POLYPROTEIN | Human immunodeficiency virus 1 | 0.2612 | |
| Chain A, POL POLYPROTEIN | Human immunodeficiency virus 1 | 0.2612 | |
| Chain B, POL POLYPROTEIN | Human immunodeficiency virus 1 | 0.2612 | |
| Chain A, Pol Polyprotein | Human immunodeficiency virus 1 | 0.2612 | |
| Chain B, Pol Polyprotein | Human immunodeficiency virus 1 | 0.2612 | |
| Prothrombin | Bos taurus (cattle) | 0.022 | |
| Gag-Pol polyprotein | HIV-1 M:B_HXB2R | 0.1852 | |
| Gag-Pol polyprotein | Human immunodeficiency virus type 1 (NEW YORK-5 ISOLATE) | 0.02 | |
| Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.018 | |
| Microsomal triglyceride transfer protein large subunit | Homo sapiens (human) | 0.054 | |
| Disintegrin and metalloproteinase domain-containing protein 17 | Homo sapiens (human) | 0.004 | |
| Envelope glycoprotein gp160 [Cleaved into: Surface protein gp120 | Human immunodeficiency virus 1 | 0.0035 | |
| Reverse transcriptase/RNaseH | Human immunodeficiency virus 1 | 0.1627 | |
| Reverse transcriptase | Human immunodeficiency virus 1 | 0.0643 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bordenave, B; Claxton, S; Henry, K; Kane, E; Klebert, M; Powderly, WG; Tebas, P; Yarasheski, K | 1 |
1 trial(s) available for glucagon and efavirenz
| Article | Year |
|---|---|
Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Blood Glucose; Body Composition; Bone Density; C-Peptide; Cyclopropanes; Drug Therapy, Combination; Female; Glucagon; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Insulin; Insulin Resistance; Lipids; Lipoproteins; Male; Nevirapine; Oxazines; Pilot Projects; RNA, Viral; Viral Load | 2004 |